Dr. Drew Carey

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as an Elite provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.

Yannis M. Paulus, M.D., F.A.C.S., is the Jonas Fridenwald Professor in Ophthalmology, an associate professor in the Johns Hopkins University Department of Ophthalmology and Department of Biomedical Engineering, and a vitreoretinal surgeon at the Wilmer Eye Institute, Johns Hopkins Medicine’s East Baltimore and Columbia locations. Dr. Paulus served as a surgical retina specialist and director of a research laboratory at the University of Michigan Kellogg Eye Center for almost 10 years, where he developed novel imaging systems, lasers and long-lasting therapies and nanotechnologies to allow physicians to determine cellular markers of disease, enabling early diagnosis, improved treatment monitoring and more individualized, personalized precision medicine tailored to each patient’s needs. After earning his bachelor’s degree in chemistry and physics from Harvard University and his medical degree at Stanford University School of Medicine, Dr. Paulus completed an internship at the Sloan-Kettering Cancer Center, a residency in ophthalmology at the Stanford University School of Medicine Byers Eye Institute, and a surgical and medical retina fellowship at Wilmer Eye Institute, Johns Hopkins Medicine. CVhttps://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Paulus_CV%2021225.pdf. Dr. Paulus is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal.

Akrit Sodhi, M.D, Ph.D., is an Associate Professor of Ophthalmology at the Wilmer Eye Institute and holds the Branna and Irving Sisenwein Professorship in Ophthalmology. Dr. Sodhi specializes in the medical and surgical management of complex vitreoretinal diseases. Dr. Sodhi was trained at the University of California at Los Angeles (UCLA), the University of California at Davis, and the National Institutes of Health. After obtaining his M.D. and Ph.D., he interned at Sinai Hospital in Baltimore and completed his Ophthalmology Residency training at the Wilmer Eye Institute at Johns Hopkins in 2008. He then pursued a fellowship in vitreoretinal surgery at Wilmer where he also served as the Assistant Chief of Service (Chief Resident). Dr. Sodhi joined the faculty of the Retina Division at Wilmer in 2010. His research interests, currently sponsored by grants from the National Eye Institute, include the examination of the role of hypoxia inducible factor (HIF) and HIF-regulated genes in ocular diseases, including diabetic eye disease, age-related macular degeneration, sickle cell retinopathy, retinal vein occlusions, and uveal melanoma. Dr. Sodhi's lab has identified novel therapeutic targets for the treatment of these vision-threatening diseases. Dr. Sodhi is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, and Late-Onset Retinal Degeneration.